Afatinib as first-line treatment in Asian patients with EGFR mutation-positive NSCLC: A narrative review of real-world evidence
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small-cell lung cancer (NSCLC). EGFR mutations are relatively common in Asian patients with NSCLC, and there is an increas...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Published: |
Springer
2021
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/26835/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|